ChemAbout

ChemAbout is a B2B platform where chemical buyers and suppliers discover each other.

Post a purchase requestList your products (for suppliers)
© 2026 ChemAbout
Compound Index|Demand Board|Insights|Exhibitions|Compliance|Help Center|Privacy Policy|Terms of Service|[email protected]
Home/Compounds/Pharmaceutical Intermediate/(2S)-2-Cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valine
C19H28N4O4
376.4 g/mol
Pharmaceutical IntermediateWarning

(2S)-2-Cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valine

CAS402958-96-7EC801-644-2
Category
Pharmaceutical Intermediate
Compound Class
Peptide
Primary Use
Pharmaceutical Intermediate

This compound is a pharmaceutical intermediate used in the manufacturing of the hepatitis C protease inhibitor telaprevir. It is a peptide-like molecule containing a pyrazine ring, a cyclohexyl group, and a tert-butyl glycine residue.

Intermediate in the synthesis of telaprevir

Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.

Sourcing this compound?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→

Related Compounds

ApplicationSame Use

(1S,3aR,6aS)-Octahydrocyclopenta[c]pyrrole-1-carboxylic acid ethyl ester hydrochloride

CAS1147103-42-1

pharmaceutical intermediate

ReferenceSame Category

Ethyl 4,6-dichloronicotinate

CAS40296-46-6

pharmaceutical intermediate

ReferenceSame Category

2-Aminopyrimidine-5-boronic acid pinacol ester

CAS402960-38-7

pharmaceutical intermediate

ReferenceSame Category

3-Fluoro-4-nitrobenzoic acid

CAS403-21-4

pharmaceutical intermediate

ReferenceSame Category

2-Fluoro-4-nitrobenzoic acid

CAS403-24-7

pharmaceutical intermediate

Related Reading

Therapeutic Peptides in 2026: This Year's Breakthroughs

2026 has been a concentrated year for peptide therapeutics. Efficacy reached a new high in late-stage trials, the obesity field moved beyond the incretins to amylin, the oral route reached weight management, and peptide-guided radioligand therapy kept advancing — each point tied to a specific 2025–2026 result.

Read more

Safety Reference

Harmful
Harmful
Warning
H302Harmful if swallowed
Identifiers
IUPAC Name

(2S)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoic acid

InChIKey

BZUKJNKTPCZNPM-LSDHHAIUSA-N

SMILES

CC(C)(C)[C@@H](C(=O)O)NC(=O)[C@H](C1CCCCC1)NC(=O)C2=NC=CN=C2

Synonyms (8)

—

Sourcing this compound?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→